|By Business Wire||
|February 11, 2013 06:00 AM EST||
InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced the 2nd Annual Langer Summit on Neurotrauma, taking place on Cape Cod in North Falmouth, MA on July 12 – 14, 2013. The Company is inviting papers in the fields of neurotrauma and SCI, and will announce the recipient of a $50,000 grant that will be given to a researcher developing novel biomaterial treatments for neurotrauma at the Summit. The award is intended to stimulate innovation and cutting-edge ideas in the fields of neuroprotection and regeneration utilizing biomaterials.
If you are a researcher in these fields, please submit your paper to InVivo Therapeutics by April 15, 2013. Your submission will be evaluated by Robert S. Langer, ScD and a panel of experts. The top author will be invited to present at the invitation-only event.
“We’ll continue what we started at the 2012 Summit, fostering a productive exchange of ideas between InVivo scientists and neurotrauma researchers with the objective of furthering the development of treatments for SCI and other neurotrauma conditions,” said InVivo CEO Frank Reynolds. Since the last Summit, we’ve been focused on advancing our scaffolding device into a first-in-man clinical trial. By the 2013 Summit, we expect to have the clinical study underway, so the Summit will focus on our growing portfolio of hydrogel technologies.”
About the Event
The Langer Summit on Neurotrauma was first held in 2012 and brought together researchers from across the world to address the challenges faced by interventions developed for spinal cord injury and other neurological conditions. The Summit is chaired by InVivo Therapeutics co-founder Robert S. Langer, ScD, the David H. Koch Institute Professor at the Massachusetts Institute of Technology. At this year’s event, participants will focus on InVivo’s expanding pipeline of 510(k) devices as well as recent innovations and their translation to the clinic.
Authors are asked to submit papers in PDF format to Lauren Mitarotondo, Vice President of Operations, at firstname.lastname@example.org.
Format: 8½”x 11” (letter size), 1-inch margins, single line spacing, full justification, 11pt Times New Roman, include page numbers. Submissions are limited to 1 page of abstract and 2 pages of body text including tables, figures and references.
Abstract: The abstract should be less than page, preceded by “Abstract:” in bold.
Authors: First name, middle initial(s), followed by the last name, should be used to identify authors. Underline the name of the presenting author. All affiliations should follow the author’s name in italics, 10 point font. If the authors come from more than one affiliation, superscript numbers should be used to indicate the correct affiliation. Each author should indicate institute, city, state, country, and email address.
Making a reference: References in the text can be made to literature listed in the “reference” section at the end by numbering the literature in superscript. The format for references should be: name of authors (initials of all names then family name, authors are separated by commas), Title of book or journal name in italics, Vol. Number in bold, pp. numbers, and year in (brackets).
Submission Deadline: April 15, 2013
Notification by: May 31, 2013
Final Version for Presentation Due: June 30, 2013
For more information please contact Lauren Mitarotondo, Vice President of Operations, at email@example.com.
Key words: Neurotrauma, neuroprotection, regeneration, spinal cord injury
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct human clinical trials for the Company’s products, the expected commencement date of any approved human clinical trials, the expected size of the pilot study, the expectation that the scaffold product will be regulated under a HDE pathway, and the expected acceleration of commercialization of the Company’s products resulting therefrom. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to obtain FDA approval to conduct human clinical trials; whether the human clinical trials produce acceptable results; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2011 and subsequent filings with the SEC.
Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.